文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

东方与西方相遇:对抗转移性结直肠癌的成功组合。

East meets West: The winning combination against metastatic colorectal cancer.

作者信息

Liu Wen-Ming, Li Xiao-Bing

机构信息

Department of Gastrointestinal Surgery, The First People's Hospital of Tianmen, Tianmen 431700, Hubei Province, China.

Department of Thoracic Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430079, Hubei Province, China.

出版信息

World J Clin Oncol. 2025 May 24;16(5):102223. doi: 10.5306/wjco.v16.i5.102223.


DOI:10.5306/wjco.v16.i5.102223
PMID:40503402
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12149826/
Abstract

Metastatic colorectal cancer (mCRC) patients with mutation have a poor prognosis despite the implementation of multiple treatment strategies. The integration of traditional Chinese medicine with Western medicine in treating mutant mCRC has garnered increasing attention. Recent studies indicate that combining traditional Chinese and modern Western medical approaches not only extend survival but also reduces the risk of mortality in patients with mutant mCRC. This approach is particularly effective for colorectal cancer patients who have right-sided colon involvement, liver metastasis, or a history of radiotherapy or chemotherapy. In this treatment combination, traditional Chinese medicine may offer symptomatic relief and improve quality of life, while Western medicine targets the disease more aggressively with advanced pharmacological agents. Ongoing research is crucial to further elucidate the mechanisms underlying these benefits and to optimize treatment protocols.

摘要

尽管实施了多种治疗策略,但携带[具体突变名称]突变的转移性结直肠癌(mCRC)患者预后较差。中西医结合治疗[具体突变名称]突变型mCRC日益受到关注。最近的研究表明,将传统中医与现代西医方法相结合,不仅可以延长[具体突变名称]突变型mCRC患者的生存期,还能降低其死亡风险。这种方法对右侧结肠受累、肝转移或有放疗或化疗史的结直肠癌患者尤为有效。在这种联合治疗中,中药可能缓解症状并改善生活质量,而西药则使用先进的药物更积极地针对疾病。持续的研究对于进一步阐明这些益处背后的机制以及优化治疗方案至关重要。

相似文献

[1]
East meets West: The winning combination against metastatic colorectal cancer.

World J Clin Oncol. 2025-5-24

[2]
Cohort study on the treatment of mutant metastatic colorectal cancer with integrated Chinese and western medicine.

World J Clin Oncol. 2025-1-24

[3]
Impact of Metastasectomy in the Multimodality Approach for V600E Metastatic Colorectal Cancer: The Mayo Clinic Experience.

Oncologist. 2017-9-13

[4]
Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study.

Chin J Cancer. 2017-10-16

[5]
Clinicopathologic features and treatment efficacy of patients with BRAF V600E-mutated metastatic colorectal cancer: a multi-center real-world propensity score matching study.

BMC Cancer. 2024-11-13

[6]
Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines.

Ann Oncol. 2021-8

[7]
and inhibition as treatment strategies in V600E metastatic colorectal cancer.

Ther Adv Med Oncol. 2021-2-22

[8]
Real-world treatment and outcomes of patients with metastatic BRAF mutant colorectal cancer.

Cancer Med. 2023-5

[9]
Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS.

Cancer Treat Res Commun. 2022

[10]
SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR V600E-mutant mCRC.

Future Oncol. 2024-4

本文引用的文献

[1]
Cohort study on the treatment of mutant metastatic colorectal cancer with integrated Chinese and western medicine.

World J Clin Oncol. 2025-1-24

[2]
Biomarker Testing Disparities in Metastatic Colorectal Cancer.

JAMA Netw Open. 2024-7-1

[3]
Molecular targeted therapy for metastatic colorectal cancer: current and evolving approaches.

Front Pharmacol. 2023-10-20

[4]
Polyphyllin I induced ferroptosis to suppress the progression of hepatocellular carcinoma through activation of the mitochondrial dysfunction via Nrf2/HO-1/GPX4 axis.

Phytomedicine. 2024-1

[5]
New insight into the mechanisms of Ginkgo biloba leaves in the treatment of cancer.

Phytomedicine. 2024-1

[6]
SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR V600E-mutant mCRC.

Future Oncol. 2024-4

[7]
Tectorigenin: A Review of Its Sources, Pharmacology, Toxicity, and Pharmacokinetics.

Molecules. 2023-8-5

[8]
Echinacoside inhibits colorectal cancer metastasis via modulating the gut microbiota and suppressing the PI3K/AKT signaling pathway.

J Ethnopharmacol. 2024-1-10

[9]
Baicalin induces ferroptosis in osteosarcomas through a novel Nrf2/xCT/GPX4 regulatory axis.

Phytomedicine. 2023-7-25

[10]
Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with wild type tumors at start of first line: The CAPRI 2 GOIM trial.

Front Oncol. 2023-2-13

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索